Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Tiziana Life Sciences LtdNASDAQ: TLSA

Gross Profit · Q4 FY2025 · quarter ended Dec 2025

Gross profit remains negative

Q4 FY2025 gross profit was -$146K, compared with -$61K a year earlier.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$146K— QoQ
Last fiscal yearDec 2025
-$234K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-139.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(234K) USD
Year-over-year change
—

Gross Profit vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 gross profit of -$234K is the 8th highest of the 9 companies compared; the peer median is -$4.32K.
TLSA Competitors Peer median
Gross Profit for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M +16.2%-9.3%69.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$7.92M +177.2%—99.8%
OKYOOKYO Pharma LimitedFY2025-$2.56K +33.7%——
EXOZeXoZymes, Inc.LTM Mar 2026-$3.64K +98.7%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$5K +100.0%——
IMMXImmix Biopharma, Inc.LTM Mar 2026-$130.77K ———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$151K -100.6%——
TLSATiziana Life Sciences LtdFY2025-$234K ———
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$711K -14.3%——
Peer median (excluding TLSA) -$4.32K+33.7%-9.3%84.9%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000234K
Gross Profit0000(234K)
Gross Margin—————
Research & Development17.82M15.92M10.25M5.23M10.28M
Selling, General & Admin1.15M4.76M8.26M10.28M10.77M
Operating Expenses36.93M17.93M22.73M15.79M21.05M
Depreciation & Amortization190.2K62.68K121.34K124K234K
EBITDA(35.53M)(18.85M)(21.66M)(16.62M)(21.05M)
EBITDA Margin—————
Operating Income(36.93M)(17.93M)(22.73M)(15.79M)(21.28M)
Operating Margin—————
Interest Income001.46M814K19K
Interest Expense237.41K8.6K12.64K6K18K
Other Income / Expenses967.18K(996.78K)937.89K(952K)2.85M
Income Before Tax(35.96M)(18.92M)(21.79M)(16.75M)(18.43M)
Pre-Tax Margin—————
Income Tax Expense(4.37M)0567.54K(4.88M)0
Net Income(31.59M)(18.92M)(22.36M)(11.86M)(18.43M)
Net Margin—————
EPS (Basic)(0.64)(0.36)(0.42)(0.22)(0.32)
EPS (Diluted)(0.64)(0.36)(0.42)(0.22)(0.32)
Weighted Avg Shares48.97M50.76M50.76M53.34M59.14M
Weighted Avg Shares (Diluted)48.97M50.76M50.76M53.34M59.14M

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.